Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 33
Filter
1.
Lupus ; 22(8): 835-8, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23817512

ABSTRACT

Systemic lupus erythematosus (SLE) patients are at increased risk of thrombosis and cardiovascular diseases. Aspirin is an effective treatment option for these patients. The aim of this study was to investigate the presence of aspirin resistance in SLE patients. We studied aspirin resistance in 33 SLE patients and nine healthy controls by using a Multiplate® impedance aggregometer (Dynabyte GmbH, Munich, Germany). Twenty-six SLE patients were on regular aspirin treatment. Aspirin resistance was found in five (19.2%) out of 26 patients who were on aspirin treatment. When the tests were repeated by adding acetylsalicylic acid in the medium, all of these patients became responsive to the aspirin. SLE disease activity, body mass index, smoking status, and the presence of anticardiolipin antibodies or positive lupus anticoagulant test results were no different in patients with or without aspirin resistance. (p>0.05 for all). Our results suggest that there may be a considerable number of SLE patients with aspirin resistance.


Subject(s)
Aspirin/therapeutic use , Fibrinolytic Agents/therapeutic use , Lupus Erythematosus, Systemic/drug therapy , Thrombosis/prevention & control , Adult , Antibodies, Anticardiolipin/blood , Aspirin/pharmacology , Case-Control Studies , Drug Resistance , Electric Impedance , Female , Fibrinolytic Agents/pharmacology , Humans , Lupus Erythematosus, Systemic/complications , Male , Middle Aged , Pilot Projects , Platelet Aggregation Inhibitors/pharmacology , Platelet Aggregation Inhibitors/therapeutic use , Platelet Function Tests , Thrombosis/etiology , Young Adult
2.
Rheumatol Int ; 32(2): 323-30, 2012 Feb.
Article in English | MEDLINE | ID: mdl-21079965

ABSTRACT

The objective of this study was to assess the effect of infliximab on depression, anxiety and quality of life in patients with active ankylosing spondylitis (AS). In this 6-week longitudinal study, 16 patients with AS were assessed. Active disease as defined by BASDAI ≥4.0 was sought for inclusion. Infliximab was administered 5 mg/kg at 0, 2 weeks and 6 weeks. Collected data included age, sex and date of onset of rheumatologic disease. Activity of disease was measured using Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). Biological activity was evaluated with erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). ESR and CRP were assessed at baseline and day 42. The Hospital Anxiety and Depression scale (HADS), Beck Depression Inventory (BDI) and 36-item Short Form Health Survey (SF-36) were used to evaluate anxiety, depression and quality of life. BASDAI, SF-36, HADS and BDE were assessed prior to the initial infliximab dose and at 2nd, 14th and 42nd day. Seven (43.8%) AS patients had depression scores above the cut off value for both the HADS depression (HADS-D) and BDI and 4 (25 %) had high HADS anxiety scores at baseline. Significant time effect for BDI and HADS-D scores were observed. Although significantly lower BDI scores were found after first, second and third infusions of infliximab, compared to initial score, the significant decrease in HADS-D appeared after second and third infusions. A significant time effect for HADS-anxiety scores were found as well. All of the subscales of SF-36 improved significantly during the course, with an exception of role emotional, for which the difference approached to the significance. The change in BASDAI scores and CRP and ESR, in the treatment process, were not correlated with the change in depression and anxiety scores. Infliximab which is an anti-TNF-α drug, may be effective in the treatment of depression accompanying AS. Possible implications for the treatment of major depressive disorder were discussed, as well.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Anxiety Disorders/drug therapy , Depressive Disorder/drug therapy , Quality of Life/psychology , Spondylitis, Ankylosing/drug therapy , Spondylitis, Ankylosing/psychology , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Adult , Antirheumatic Agents/therapeutic use , Anxiety Disorders/immunology , Anxiety Disorders/psychology , Depressive Disorder/immunology , Depressive Disorder/psychology , Female , Humans , Infliximab , Longitudinal Studies , Male , Middle Aged , Spondylitis, Ankylosing/immunology
3.
Clin Exp Rheumatol ; 25(4 Suppl 45): S16-20, 2007.
Article in English | MEDLINE | ID: mdl-17949546

ABSTRACT

OBJECTIVE: Familial Mediterranean fever (FMF) is the most common auto-inflammatory syndrome with exaggerated acute phase and inflammatory response. After revealing the MEFV gene mutation with the finally disturbed end product pyrin, some of the mechanisms were explained. However it is still unknown what triggers or ends these periodical attacks. Moreover, the treatment of up to 30% of the patients, that are resistant to colchicine is still a problem. In this study we investigated the role of serotonin in colchicine-resistant FMF patients. METHODS: Twenty-four FMF patients (male/female: 15/9) and 32 age- and sex-matched healthy controls (male/female: 17/15) were included into the study. Patients were subdivided into two groups. Thirteen had FMF attacks despite regular colchicine (colchicine-resistant group), other 11 had disease under control with colchicine for at least 6-months. Sampling was done both during the attack and ten days after its cessation. Plasma and platelet serotonin levels and acute phase reactants were studied in patients and controls. RESULTS: Colchicine-resistant patients had plasma serotonin (5-HT) levels of 7.85 +/- 1.0 nmol/l during acute attacks which significantly reduced to the levels of 6.3 +/- 0.6 nmol/l (p < 0.001), after 10 days of acute attacks and these levels were significantly lower than those of attack-free patients' and controls' (10.7 +/- 0.2 nmol/l and 10.1 +/- 0.3 nmol/l, respectively). Platelet 5-HT level was 6.4 +/- 0.3 nmol/10(9) platelets during acute attack, and this level was increased to 9.8 +/- 0.5 nmol/10(9) platelets on the 2(nd) sampling, 10 days after the cessation of the acute attack (p < 0.001). They were both significantly higher than those of attack-free FMF patients (5.9 +/- 0.1 nmol/10(9) platelets) and healthy controls (5.7 +/- 0.3 nmol/10(9) platelets). There was a negative correlation between plasma and platelet 5-HT levels (r=-0.77, p < 0.001). CONCLUSION: Changes in plasma and platelet 5-HT levels may be related to the disturbances in 5-HT transport mechanisms or may also be attributed to the potential role of serotonin in the inflammatory cascade. Last but not least, serotonin may have a role in the pathogenesis of FMF.


Subject(s)
Blood Platelets/drug effects , Drug Resistance/drug effects , Familial Mediterranean Fever/blood , Familial Mediterranean Fever/drug therapy , Selective Serotonin Reuptake Inhibitors/pharmacology , Serotonin/blood , Adolescent , Adult , Case-Control Studies , Colchicine/pharmacology , Drug Resistance/physiology , Female , Gout Suppressants/pharmacology , Humans , Inflammation/blood , Inflammation/drug therapy , Male , Middle Aged , Serotonin Plasma Membrane Transport Proteins/drug effects
4.
Clin Exp Rheumatol ; 24(3): 305-8, 2006.
Article in English | MEDLINE | ID: mdl-16870099

ABSTRACT

OBJECTIVE: Presence of extra-articular manifestations (EAM) in rheumatoid arthritis (RA) is associated with more severe disease and increased mortality. Prevalence of EAM may vary in different geographic areas and in different ethnic populations. In this study we investigated the frequency of EAM in 526 RA patients from a single university hospital in Turkey. METHODS: The hospital records of patients who had been diagnosed as RA in Hacettepe University Department of Rheumatology between the years 1988 and 2003 were retrospectively evaluated. There were 73 males and 453 females, and mean age of the patients was 48.0 +/- 12.3 years. The mean follow-up period was 4.8 +/- 4.1 years. Three hundred and fifty-nine patients were rheumatoid factor (RF) positive (68.3%). RESULTS: The overall frequency of EAM was 38.4% (202 patients). The most common EAM was rheumatoid nodules (18.1%). Sicca symptoms, pulmonary findings, Raynaud's phenomenon, livedo reticularis, carpal tunnel syndrome, vasculitis, amyloidosis, and Felty syndrome were present in 11.4%, 4.8%, 3%, 4.8%, 2.8%, 1.3%, 1.1%, and 0.3% of the patients, respectively. Overall EAM and rheumatoid nodules were significantly more common in RF positive patients than RF negative patients. The frequency of rheumatoid nodules was significantly higher in males than in females. CONCLUSION: The prevalence of EAM in Turkey is higher than East Asia and Africa, and lower than UK and North America. Excluding secondary Sjögren's syndrome, our results are similar to other Mediterranean populations like Italy.


Subject(s)
Arthritis, Rheumatoid/complications , Lung Diseases/complications , Raynaud Disease/complications , Rheumatoid Nodule/etiology , Sjogren's Syndrome/complications , Skin Diseases, Vascular/complications , Adolescent , Adult , Aged , Aged, 80 and over , Arthritis, Rheumatoid/pathology , Comorbidity , Female , Hospitals, University , Humans , Lung Diseases/pathology , Male , Middle Aged , Raynaud Disease/pathology , Retrospective Studies , Rheumatoid Nodule/pathology , Sjogren's Syndrome/pathology , Skin Diseases, Vascular/pathology , Turkey/epidemiology
5.
Clin Exp Rheumatol ; 23(4 Suppl 38): S77-80, 2005.
Article in English | MEDLINE | ID: mdl-16273770

ABSTRACT

OBJECTIVE: Familial Mediterranean fever (FMF) attacks are characterized by serosal inflammation rich in PMNL leukocytes and activation of a definite cytokine network. Moreover, there is sustained inflammation in attack-free FMF patients. Interleukin (IL)-17 and IL-18 are recently described proinflammatory cytokines, which can modulate certain neutrophil functions. In this study we measured serum levels of IL-17 and IL-18 in FMF patients. METHODS: The study groups comprised of 18 FMF patients in attack-free period (mean age: 30.2 +/- 9.5 years; male/female: 10/8), and 18 patients with an acute FMF attack (mean age: 25.4 +/- 4.9 years; male/female: 10/8). Twenty age-matched healthy subjects were included as a control group (male/female: 10/10). Levels of IL-17 and IL-18 were determined by commercial ELISA kits (Biosource International, USA). RESULTS: Serum IL-17 levels were 42.8 +/- 3.7, 42.7 +/- 3.2, and 39.9 +/- 2.3 pg/mL for FMF patients in attack-free period, FMF patients with acute attack, and healthy controls, respectively. Serum IL-18 levels were 878.8 +/- 315.0, 854.2 +/- 261.4, and 314.6 +/- 80.8 pg/mL for FMF patients in an attack-free period, FMF patients with acute attack, and healthy controls, respectively. Levels of both IL-17 and IL-18 were significantly higher in FMF patients with and without acute attack compared to control group (p < 0.05). Concentrations of those cytokines were comparable in FMF patients with acute attack and in attack-free period (p > 0.05). CONCLUSION: Our data suggest that IL-17 and IL-18 contribute to the cytokine network in the inflammatory cascade of FMF. However, their roles for the initiation of FMF attacks remain to be established.


Subject(s)
Familial Mediterranean Fever/blood , Interleukin-17/blood , Interleukin-18/blood , Acute Disease , Acute-Phase Proteins/analysis , Adult , Enzyme-Linked Immunosorbent Assay , Familial Mediterranean Fever/etiology , Familial Mediterranean Fever/pathology , Female , Humans , Male
6.
Clin Exp Rheumatol ; 22(4 Suppl 34): S41-4, 2004.
Article in English | MEDLINE | ID: mdl-15515783

ABSTRACT

OBJECTIVE: About 10-20% of familial Mediterranean fever (FMF) patients are resistant to regular colchicine treatment and have painful recurrent attacks due to polyserositis. In clinical practice there is no alternative drug for such patients. In a previous pilot study on a small number of colchicine-resistant patients, interferon-alpha (IFN-alpha) was administered when painful attacks were about to occur. METHODS: In this study we gave IFN-alpha continuously to 8 colchicine-resistant FMF patients in a schedule while the colchicine therapy had been continued. All those patients were complicated with vasculitis or arthritis or together during the FMF course. Those complications were treated with the other immunosuppressive drugs. While they were under intense immunosuppressive therapy, the abdominal and the other serosal attacks remained to continue. RESULTS: After the administration of IFN-alpha therapy only one out of eight patients had abdominal painful attacks in twice, and one patient had arthritis in knees and ankles, the others responded well. Observed side effects were generally mild and acceptable. CONCLUSION: Continuous IFN administration in addition to the regular colchicine treatment may be useful for the colchicine-resistant attacks in FMF patients.


Subject(s)
Adjuvants, Immunologic/administration & dosage , Colchicine/therapeutic use , Drug Resistance/drug effects , Familial Mediterranean Fever/drug therapy , Immunosuppressive Agents/therapeutic use , Interferon-alpha/administration & dosage , Adult , Drug Therapy, Combination , Familial Mediterranean Fever/complications , Familial Mediterranean Fever/pathology , Female , Humans , Male , Serositis/drug therapy , Serositis/etiology , Serositis/pathology
8.
Clin Exp Rheumatol ; 22(2): 223-6, 2004.
Article in English | MEDLINE | ID: mdl-15083891

ABSTRACT

OBJECTIVE: The aim of this study was to determine the outcome of patients with systemic rheumatic diseases admitted to our medical-intensive care unit (ICU) in comparison to the outcome of patients with non-rheumatic diseases in the same ICU. METHODS: The hospital files of 50 patients with systemic rheumatic diseases who were treated in the medical-ICU of Hacettepe University Hospital, Ankara between 1995 and 2001 were retrospectively evaluated. 50 patients without any underlying systemic rheumatic diseases admitted to the medical-ICU in the same time period and matched for age, gender and acute physiology and chronic health evaluation scores were included in the control group. ICU outcome was compared between the two groups. RESULTS: The acute physiology score of the study group was lower than that of the control group (13.4 +/- 5.7 [SD] vs. 17.3 +/- 7.2, p = 0.04). Moreover, the study group received more immunosuppressive treatment but less invasive procedures (i.e. mechanical ventilation and central venous catheterization). Mortality rates (56% vs. 54%, respectively, p = 0.5), lengths of stay in the ICU and in the hospital, the infection rates were similar between the rheumatic disease group and the control group. CONCLUSION: The presence of a systemic rheumatic disease seems to negatively affect the outcome in patients under intensive care.


Subject(s)
Cause of Death , Critical Care , Rheumatic Diseases/mortality , Cohort Studies , Critical Care/statistics & numerical data , Female , Hospitals, University , Humans , Intensive Care Units , Male , Retrospective Studies , Rheumatic Diseases/complications , Rheumatic Diseases/therapy , Turkey/epidemiology
9.
Clin Rheumatol ; 22(4-5): 289-94, 2003 Oct.
Article in English | MEDLINE | ID: mdl-14579158

ABSTRACT

Pharmacological treatment of diffuse systemic sclerosis (SSc) directed at the tissue fibrosis has generally been ineffective. Many immunosuppressive drugs have been tried as therapy for SSc, regardless of the disease subtype and/or stage. The aim of this study was to show the efficacy and the toxicity of oral cyclophosphamide and prednisolone therapy on the prevention of fibrosis-based tissue damage in the early stages of the diffuse SSc. Twenty-seven patients with early diffuse SSc were treated with oral cyclophosphamide (1-2 mg/kg/day) plus oral prednisolone (40 mg/every other day) between the years 1995 and 1998. The results regarding the efficacy and toxicity of cyclophosphamide were compared with those of 22 early SSc patients who had been treated with oral D-penicillamine between 1992 and 1995. All the patients were evaluated using clinical and laboratory parameters every 6 months for 2 years. There was a significant improvement on the skin score, maximal oral opening, flexion index, predicted forced vital capacity (FVC) and carbon monoxide diffusing capacity (DLCO) in the cyclophosphamide group. The decrease in skin score in the cyclophosphamide group started earlier than in the D-penicillamine group. No life-threatening or irreversible adverse reaction was observed. This open study supports the use of oral cyclophosphamide plus prednisolone therapy to prevent fibrosis and its complications in the early stages of diffuse SSc.


Subject(s)
Cyclophosphamide/administration & dosage , Prednisolone/administration & dosage , Scleroderma, Systemic/drug therapy , Administration, Oral , Adult , Cohort Studies , Cyclophosphamide/adverse effects , Dose-Response Relationship, Drug , Drug Administration Schedule , Drug Therapy, Combination , Female , Follow-Up Studies , Humans , Male , Middle Aged , Prednisolone/adverse effects , Probability , Prospective Studies , Risk Assessment , Scleroderma, Systemic/diagnosis , Severity of Illness Index , Statistics, Nonparametric , Treatment Outcome
10.
J Int Med Res ; 31(4): 345-9, 2003.
Article in English | MEDLINE | ID: mdl-12964513

ABSTRACT

This study aimed to assess the frequency of all palpable lymph nodes during active disease and remission in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Hospital records of 100 SLE patients, 100 RA patients, 100 spondyloarthropathy patients, and 150 osteoarthritis patients, treated in our rheumatology department, were evaluated retrospectively. Overall frequencies of enlarged lymph nodes in patients with active RA and SLE were 82% and 69%, respectively. Enlarged lymph nodes associated with RA were mostly located in the axillary region, and in SLE the nodes were smaller and lymphadenopathy was more generalized compared with RA. Palpable lymph nodes disappeared in the majority of patients during remission. Lymphadenopathy was significantly less frequent in patients treated with steroids before admission. Lymph node enlargement is an important physical finding associated with RA and SLE disease activity. Atypical locations and unusually large lymph nodes should raise clinical suspicion of another underlying disease.


Subject(s)
Arthritis, Rheumatoid/complications , Lupus Erythematosus, Systemic/complications , Lymph Nodes/pathology , Lymphatic Diseases/etiology , Adult , Aged , Arthritis, Rheumatoid/pathology , Diagnosis, Differential , Female , Humans , Lupus Erythematosus, Systemic/pathology , Male , Middle Aged , Retrospective Studies
12.
Clin Rheumatol ; 21(6): 453-6, 2002 Nov.
Article in English | MEDLINE | ID: mdl-12447626

ABSTRACT

Thrombopoietin (TPO) is the major regulator of growth and differentiation of megakaryocytes. Recent studies have shown that TPO may also act as an acute-phase reactant, and it has been suggested as a component of inflammatory reactions. In this study our objective was to investigate serum TPO levels in patients with rheumatoid arthritis, a complex chronic inflammatory disorder not uncommonly associated with thrombocytosis. Bloodstream TPO concentrations were assessed in 13 RA patients with platelet counts between 450 and 650 x 10(9)/l, 10 RA patients with platelet counts >650 x 10(9)/l, 15 RA patients with normal platelet counts and 12 healthy controls. RA patients with normal platelet counts had TPO levels comparable with healthy controls. TPO concentrations in patients with mild thrombocytosis were significantly elevated, whereas patients with markedly increased thrombocyte counts had prominently decreased TPO levels. These results indicate that TPO seems to be associated with reactive thrombocytosis in RA patients with active disease. In patients with extremely increased thrombocytosis serum TPO levels might be regulated by increased platelet mass via receptor-mediated uptake and metabolism.


Subject(s)
Arthritis, Rheumatoid/blood , Thrombocytosis/blood , Thrombopoietin/blood , Adult , Arthritis, Rheumatoid/complications , Arthritis, Rheumatoid/physiopathology , Female , Humans , Joints/physiopathology , Male , Platelet Count , Thrombocytosis/etiology
13.
Ann Rheum Dis ; 60(12): 1149-51, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11709459

ABSTRACT

BACKGROUND: Tissue factor pathway inhibitor (TFPI) is an anticoagulant which modulates the tissue factor (TF) dependent pathway, acting on the factor VIIa/TF complex, factor Xa, and thrombin. Although most TFPI is found in association with plasma lipoproteins and platelets, the functional pool is bound to vascular endothelium and is released into the circulation on stimulation with heparin or low molecular weight heparin (LMWH). OBJECTIVE: To assess the vascular endothelial TFPI pool in patients with Behçet's disease (BD) or systemic lupus erythematosus (SLE). METHODS: Plasma TFPI concentrations were determined before, and 20 and 60 minutes after subcutaneous LMWH injection in 15 newly diagnosed patients with BD and 12 with SLE, and in 12 healthy controls. RESULTS: Baseline median TFPI was 149.5 ng/ml in healthy subjects, and the percentage change in TFPI at 20 minutes (((value at 20th min - baseline value)/baseline value) x 100) was 575.2. TFPI concentrations in patients with BD were initially normal at baseline (136.0 ng/ml), but the percentage change (44.7) was significantly lower than in the patients with SLE and the controls. Baseline TFPI concentrations in patients with SLE (83.0 ng/ml) were lower than in the control group, but the TFPI response to stimulation with LMWH reached a level (626.4%) comparable to that of the controls. CONCLUSION: Depletion of the functional endothelial pool in BD and low circulating concentrations of TFPI despite an intact pool in SLE may be important in the pathogenesis of thrombosis in these vasculitic syndromes.


Subject(s)
Behcet Syndrome/blood , Lipoproteins/blood , Lupus Erythematosus, Systemic/blood , Thrombophilia/blood , Adult , Behcet Syndrome/complications , Blood Specimen Collection/methods , Factor Xa Inhibitors , Female , Fibrinolytic Agents , Heparin, Low-Molecular-Weight , Humans , Lupus Erythematosus, Systemic/complications , Male , Serine Proteinase Inhibitors/blood , Thrombophilia/etiology
14.
Rheumatol Int ; 20(6): 217-20, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11563578

ABSTRACT

We assessed plasma concentrations of fibronectin (FN) and thrombospondin (TSP) during acute attacks and attack-free periods of patients with familial Mediterranean fever (FMF). Seven female and three male FMF patients (mean age 34+/-7 years) were enrolled in the study. Plasma samples were obtained during acute FMF attacks and after 3 months of freedom from attacks. Erythrocyte sedimentation rate, C-reactive protein, and white blood cell count were evaluated concurrently. Plasma levels of FN and TSP were assayed by enzyme-linked immunosorbent assay (ELISA). Both FN and TSP concentrations were found to increase during acute attacks. Levels of adhesive molecules decreased during attack-free periods (P < 0.05). Significant correlations were found between FN and TSP levels and the concentrations of acute-phase response indicators (P< 0.05). This study disclosed for the first time significantly higher increments in the plasma levels of FN and TSP during acute FMF attacks than in attack-free periods. Therefore, the two matrix glycoproteins may play precipitating and/or regulatory roles in the inflammatory processes of these attacks.


Subject(s)
Familial Mediterranean Fever/blood , Fibronectins/blood , Thrombospondins/blood , Adult , Biomarkers/blood , Cross-Sectional Studies , Familial Mediterranean Fever/diagnosis , Female , Fibronectins/analysis , Humans , Male , Probability , Prospective Studies , Recurrence , Reference Values , Sensitivity and Specificity , Severity of Illness Index , Statistics, Nonparametric
16.
Ann Nucl Med ; 15(2): 117-21, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11448069

ABSTRACT

Diagnosis of sacroiliitis (SI) with bone scintigraphy may involve difficulties even with a quantitative approach. The aim of this study was to evaluate the combined use of bone and bone marrow scintigraphies for the diagnosis of active sacroiliitis. Thirty-one patients who were clinically suspected to have SI were included in the study. Bone and bone marrow scintigraphies were done after injections of 740 MBq of 99mTc-MDP (MDP) and 370 MBq of 99mTc-sulfur colloid (SC) respectively with a 2-day interval. Both visual and quantitative assessment of MDP uptake and visual assessment of SC uptake in sacroiliac joints were performed. Also sacroiliac joint radiographic findings for each patient were evaluated and graded from 0 to 4 according to the New York grading system. Patients were divided into 2 groups according to their x-ray findings (Group A: grade 0-2, Group B: grade 3-4). A total of 14 patients (10 bilateral, 4 unilateral) had increased MDP uptake with decreased/normal SC uptake. Twelve of 14 patients had grade 0-2 radiographic changes while only 2 patients had grade 3-4 radiographic changes. Increased MDP uptake with decreased/normal SC uptake is the most common scintigraphic pattern seen in acute phase SI in which radiographic findings are generally found to be normal or slightly changed. In at least in 8 patients the decreased bone marrow uptake of SC was demonstrated, supporting the diagnosis. Although our results did not reveal any significant superiority of bone marrow scintigraphy to bone scan for the detection of active sacroiliitis, combined use of bone and bone marrow scintigraphies was presented as an alternative method to characterize patients with active sacroiliitis.


Subject(s)
Arthritis/diagnostic imaging , Bone Marrow/diagnostic imaging , Bone and Bones/diagnostic imaging , Sacroiliac Joint/diagnostic imaging , Adult , Arthritis/diagnosis , Female , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Radionuclide Imaging , Radiopharmaceuticals , Sacroiliac Joint/pathology , Technetium Tc 99m Medronate , Technetium Tc 99m Sulfur Colloid
17.
Clin Exp Rheumatol ; 19(5 Suppl 24): S37-41, 2001.
Article in English | MEDLINE | ID: mdl-11760396

ABSTRACT

OBJECTIVE: To investigate the synovial fluid levels of interleukin-1 beta (IL-1 beta), tumour necrosis factor-alpha (TNF-alpha), transforming growth factor-beta (TGF-beta), IL-1 receptor antagonist (IL-1ra), soluble IL-2 receptor (sIL-2r) and IL-8 in patients with Behçet's disease (BD) and to compare them to levels in rheumatoid arthritis (RA), and osteoarthritis (OA). METHODS: The cytokine levels of BD (n = 14), RA (n = 15) and OA (n = 15) patients were assessed by enzyme-linked immunosorbent method. RESULTS: Median synovial IL-1 beta and TNF-alpha levels were higher in RA compared to BD and OA patients. IL-1 beta levels were also higher in BD than OA whereas TNF levels were similar in these two groups. IL-1ra and TGF-beta activity in BD were higher than OA but lower than RA. sIL-2r and IL-8 levels were increased in BD and RA in comparison to OA patients. CONCLUSION: The arthritis of BD is non-erosive and accordingly, its synovial fluid contains lower levels of cytokines primarily involved in cartilage destruction, namely IL-1 beta and TNF-alpha, than RA. IL-1ra and TGF might serve as protective factors against erosion in the inflamed joints. High synovial fluid levels of sIL-2r and IL-8 probably reflect a non-specific inflammatory process.


Subject(s)
Behcet Syndrome/immunology , Cytokines/analysis , Synovial Fluid/immunology , Adult , Arthritis, Rheumatoid/immunology , Enzyme-Linked Immunosorbent Assay , Female , Humans , Interleukin-1/analysis , Interleukin-8/analysis , Lymphotoxin-alpha/analysis , Male , Middle Aged , Osteoarthritis/immunology , Receptors, Interleukin-1/analysis , Receptors, Interleukin-2/analysis , Tumor Necrosis Factor-alpha/analysis
18.
Clin Exp Rheumatol ; 19(5 Suppl 24): S25-9, 2001.
Article in English | MEDLINE | ID: mdl-11760394

ABSTRACT

OBJECTIVE: Nitric oxide (NO) is produced in increased amounts in inflammatory conditions and may cause tissue injury by reacting with superoxide to yield peroxynitrite, a powerful toxin. Superoxide dismutase (SOD) scavenges superoxide and inhibits the formation of peroxynitrite, thereby suppressing the resulting injury and regulating the bioavailability of NO. We conducted a study to assess serum NO and SOD in patients with Behçet's disease (BD) and correlate their levels with disease activity. METHODS: Serum NO concentrations and SOD activities were determined in 25 BD patients (mean age: 36 years; male/female: 13/12) and in 15 healthy controls. BD patients were allocated into two groups according to disease activity (active/inactive: 11/14). RESULTS: In patients with active disease, NO levels were found to be significantly elevated, while SOD activities were comparable to the control group. Conversely, patients with inactive disease exhibited markedly high SOD activities and normal NO levels. Moreover, there was a positive correlation between SOD activity and NO levels in patients with inactive BD (r = 0.562, p < 0.05). CONCLUSION: We propose that NO-associated injury of tissues, particularly the endothelium, may be important in the etiopathogenesis of vasculitis in BD, and SOD may play a protective role against inflammation.


Subject(s)
Behcet Syndrome/blood , Nitric Oxide/blood , Superoxide Dismutase/blood , Adolescent , Adult , Female , Humans , Male , Nitric Oxide/metabolism , Severity of Illness Index , Superoxide Dismutase/metabolism
19.
Nagoya J Med Sci ; 63(3-4): 115-22, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11201985

ABSTRACT

OBJECTIVE: Cold intolerance, cold induced peripheral vasospasm, Raynaud's phenomenon, livedo reticularis and immunoglobulin deposition in the skin are often encountered clinical and laboratory findings in patients with primary fibromyalgia (FM). These findings are suggestive of vascular injury. METHODS: Eighty patients (4 male, 76 female) with fulfilling primary FM criteria (FM (+) patient group), 60 patients (3 male, 57 female) with chronic musculoskeletal complaints but without FM (FM (-) patient control group) and 40 healthy volunteers (1 male, 39 female) without musculoskeletal complaints (healthy control group) were enrolled in this cross-sectional study. The study was carried out in two steps. In the first step, the clinical findings, routine laboratory tests, autoantibodies and radiological findings were investigated. The second step were consisted of the laboratory investigations of thrombomodulin and fibronectin as the mediators indicating vascular injury and proinflammatory cytokines in FM patients with Raynaud's phenomenon and/or livedo reticularis and in control groups. RESULTS: There were no differences between study and control groups with regard to laboratory, radiological and immunological (ANA, AntidsDNA, ENA, anticardiolipin IgG and IgM) results. No statistically significant differences were found in the levels of proinflammatory cytokines between FM (+) patient group and control groups (p > 0.05). Thrombomodulin was also shown statistically insignificant difference between FM (+) patient group and control groups (p > 0.05). However, fibronectin, another mediator of vascular injury, was higher in FM (+) patient group and the differences between FM (+) patients and each control groups were statistically significant (p < 0.0001). CONCLUSION: Our results were suggestive of the presence of a non-immunological vascular injury in FM patients with Raynaud's phenomenon and/or livedo reticularis.


Subject(s)
Blood Vessels/injuries , Fibromyalgia/physiopathology , Inflammation Mediators/blood , Adult , Case-Control Studies , Cytokines/blood , Female , Fibromyalgia/complications , Fibronectins/blood , Humans , Male , Middle Aged , Raynaud Disease/etiology , Skin Diseases, Vascular/etiology , Thrombomodulin/blood
20.
Lupus ; 8(9): 737-41, 1999.
Article in English | MEDLINE | ID: mdl-10602446

ABSTRACT

Systemic lupus erythematosus (SLE) is a systemic autoimmune disorder with overwhelming thrombotic states. The precise pathogenetic mechanisms underlying the prethrombotic state in SLE is not fully understood, but interactions between the antiphospholipid antibodies and antigen targets on the coagulation components have been incriminated to play fundamental roles. To evaluate this issue, 34 women with antiphospholipid antibody negative SLE were investigated for molecular markers of blood coagulation and fibrinolytic activity: prothrombin fragment1+2 (PF1+2), thrombin-antithrombin complex (TAT), plasmin-alpha2-antiplasmin inhibitor complex (PAP), and tissue factor pathway inhibitor (TFPI). We also analysed plasma soluble thrombomodulin (sTM) levels. SLE disease activity was determined using the SLE Disease Activity Index (SLEDAI). Concentrations of TAT, PAP, PF1+2 and sTM were significantly elevated (P<0.0001, P=0.0002, P<0.0001, and P<0.0001, respectively), while TFPI antigen levels were found to be reduced (P<0.0001) in patients with SLE compared to the control group. In patients with active SLE, anti-ds DNA levels were correlated positively with plasma TAT (P<0.05), PF1+2 (P<0.05), and sTM (P<0.01) concentrations and negatively with plasma TFPI levels (P<0.05). SLEDAI scores were correlated positively with plasma TAT (P<0.01), PF1+2 (<0.01), and sTM (P<0.01) levels. This study illustrates that both a prethrombotic state and a compensatory fibrinolytic process secondary to subclinical intravascular coagulation might coexist in SLE with elevated sTM levels, indicating impaired endothelial functions.


Subject(s)
Hemostasis , Lupus Erythematosus, Systemic/blood , Thrombomodulin/blood , Adult , Autoantibodies/blood , Female , Humans , Lupus Erythematosus, Systemic/immunology , Middle Aged , Thrombosis/blood , Thrombosis/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...